Trial · NCT07321912
Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
NCT07321912, Phase 2, Recruiting, Milton S. Hershey Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma. Trials, record NCT07321912. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07321912
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
- NCT number
- NCT07321912
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 406 participants, estimated
- Lead sponsor
- Milton S. Hershey Medical Center
- Conditions
- Osteosarcoma, Ewing Sarcoma
- Interventions
- Eflornithine, Topotecan, Cyclophosphamide, Vincristine, Doxorubicin, Ifosfamide, Etoposide, Cisplatin, Methotrexate
- First posted
- 2026-01-07
- Last updated
- 2026-10-06
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Cohort 1 participants with relapse free survival (RFS) during study | 2 years plus 5 years follow up | Cohort 1: To determine if relapse-free survival (RFS) in participants with relapsed or refractory Ewing sarcoma treated with multiagent chemotherapy is improved with the addition of DFMO as compared to historical outcomes of participants treated with the same multiagent chemotherapy without DFMO. |
| Primary | Number of Cohort 2 participants with event-free survival (EFS) during study | 2 years plus 5 years follow up | Cohort 2: To determine if event-free survival (EFS) in participants with newly diagnosed metastatic Ewing sarcoma treated with multiagent chemotherapy is improved with the addition of DFMO as compared to historical outcomes of participants treated with the same multiagent chemotherapy without DFMO. |
| Primary | Cohort 3: Number of Cohort 3 participants at 12 months with disease control | 1 year plus 5 years follow up | To determine the 12-month disease control rate (DCR) in participants with completely resected recurrent osteosarcoma treated with DFMO as compared to historical controls. |
| Primary | Cohort 4A: Number of Cohort 4A participants with event-free survival (EFS) during study | 2 years plus 5 years follow up | Examine whether the addition of DFMO to post-operative chemotherapy with cisplatin, doxorubicin, and methotrexate (MAP) improves the event-free survival (EFS) for participants with osteosarcoma having localized disease with a poor histological response to 10 weeks of pre-operative chemotherapy. |
| Primary | Cohort 4B: Number of Cohort 4B participants with event-free survival (EFS) during study | 2 years plus 5 years follow up | Examine whether the addition of DFMO to post-operative chemotherapy with cisplatin, doxorubicin, and methotrexate (MAP) improves the event-free survival (EFS) for participants with osteosarcoma with metastatic disease at diagnosis (Cohort 4B). |
| Secondary | Length of time that participants experience Overall Survival (OS) | 10 Years | To compare overall survival in DFMO-treated participants versus historical controls. |
| Secondary | Number of Participants with Adverse Events as a Measure of Safety and Tolerability | 2 years | To characterize safety and tolerability of DFMO plus multiagent chemotherapy. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07321912
GET https://conductscience.org/api/trials/v1/NCT07321912/registered